Anteis announces new partnership with Sanofi-Aventis

Anteis announces new partnership with Sanofi-Aventis

Plan-les-Ouates/Genève, January 4, 2010 – Anteis announces today that it has concluded with Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) a supply and distribution partnership between the two companies for SUCCEEV, a Hyaluronic Acid (HA) based dermal filler.

Available in Europe, Asia-Pacific, South America and the Middle East, SUCCEEV is a Hyaluronic Acid based dermal filler which includes three formulations, allowing correction of different types of wrinkles (fine lines to deep wrinkles) and lip augmentation.

“Anteis is pleased to be the partner of choice for Sanofi-aventis,” said Stéphane Mendras Anteis Director of Business Development. “Over recent years, Anteis has built its reputation as having unique expertise in the development of hyaluronic acid based products for aesthetic dermatology. This alliance will mean that our highly effective and reliable products will now be available to an even larger group of practitioners and their patients worldwide.”

The partnership comes ahead of a global move from Sanofi-aventis to launch its highly anticipated medical aesthetics business which is expected for January 2010.

“In line with our core business platform, Sanofi-aventis anticipates providing additional sustainable options for healthcare professionals globally, as well as offering more options for patients in all markets” said Scott McLennan, Global Marketing Medical Aesthetics and Dermatology Franchise Manager APRS Sanofi-aventis.

“Sanofi-aventis has identified a solid opportunity for growth across all the major markets in medical aesthetics,” added McLennan.

About Anteis

Anteis is a Swiss company specializing in the development, manufacturing and distribution of injectable medical devices based on biopolymer transformation in aesthetic dermatology, ophthalmology and orthopaedics. Based in Plan-les-Ouates/Geneva, Anteis employs an international team of 150 persons, has subsidiaries in Annecy and Munich and a distribution network covering 90 countries.

For further information: www.anteis.com

About Sanofi-aventis:

Sanofi-aventis, a leading global pharmaceutical company, discovers, develops and distributes therapeutic solutions to improve the lives of everyone. Sanofi-aventis is listed in Paris (EURONEXT : SAN) and in New York (NYSE : SNY).